3//SEC Filing
Foresite Capital Opportunity Fund V, L.P. 3
Accession 0001209191-20-061352
CIK 0001797768other
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 6:03 AM ET
Size
25.5 KB
Accession
0001209191-20-061352
Insider Transaction Report
Form 3
Foresite Capital Management IV, LLC
10% Owner
Holdings
- (indirect: See Footnote)
Series A Preferred Stock
→ Common Stock (298,465 underlying) - (indirect: See Footnote)
Series C Preferred Stock
→ Common Stock (157,748 underlying) - (indirect: See Footnote)
Series B Preferred Stock
→ Common Stock (55,922 underlying) - (indirect: See Footnote)
Series B Preferred Stock
→ Common Stock (18,641 underlying) - (indirect: See Footnote)
Series C Preferred Stock
→ Common Stock (145,614 underlying) - (indirect: See Footnote)
Series B Preferred Stock
→ Common Stock (2,666,002 underlying) - (indirect: See Footnote)
Series A Preferred Stock
→ Common Stock (6,347,893 underlying) - (indirect: See Footnote)
Series C Preferred Stock
→ Common Stock (48,538 underlying) - (indirect: See Footnote)
Series A Preferred Stock
→ Common Stock (99,488 underlying)
Footnotes (6)
- [F1]Each share of the issuer's Series A Preferred Stock will automatically convert into one share of common stock immediately prior to the completion of the issuer's initial public offering and has no expiration date.
- [F2]The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
- [F3]The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
- [F4]The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
- [F5]Each share of the issuer's Series B Preferred Stock will automatically convert into one share of common stock immediately prior to the completion of the issuer's initial public offering and has no expiration date.
- [F6]Each share of the issuer's Series C Preferred Stock will automatically convert into 1.00335008 shares of common stock immediately prior to the completion of the issuer's initial public offering and has no expiration date.
Documents
Issuer
Kinnate Biopharma Inc.
CIK 0001797768
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001792205
Filing Metadata
- Form type
- 3
- Filed
- Dec 2, 7:00 PM ET
- Accepted
- Dec 3, 6:03 AM ET
- Size
- 25.5 KB